
Jeffrey S Heier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9395664/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Ophthalmology, 2022, 129, 974-985.	2.5	28
2	Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion–Related Events with Brolucizumab. Ophthalmology, 2021, 128, 1050-1059.	2.5	196
3	Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Neovascular Age-Related Macular Degeneration. Journal of Clinical Medicine, 2021, 10, 1355.	1.0	17
4	Altered Blood Flow in the Ophthalmic and Internal Carotid Arteries in Patients with Age-Related Macular Degeneration Measured Using Noncontrast MR Angiography at 7T. American Journal of Neuroradiology, 2021, 42, 1653-1660.	1.2	13
5	Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration. Ophthalmology, 2020, 127, 186-195.	2.5	306
6	Intravitreal Combined AfliberceptÂ+ Anti–Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2020, 127, 211-220.	2.5	12
7	Visual Function Decline Resulting from Geographic Atrophy. Ophthalmology Retina, 2020, 4, 673-688.	1.2	44
8	Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on Outcomes in the COPERNICUS and GALILEO Studies. Ophthalmology Retina, 2019, 3, 553-560.	1.2	4
9	Outcomes and Practice Preferences After Endophthalmitis Following Anti-VEGF Intravitreal Injection. Journal of Vitreoretinal Diseases, 2019, 3, 411-419.	0.2	3
10	Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study. Ophthalmology Retina, 2019, 3, 32-41.	1.2	19
11	Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration. Ophthalmology, 2018, 125, 1556-1567.	2.5	100
12	The Potential Importance of Detection of Neovascular Age-Related Macular Degeneration When Visual Acuity Is Relatively Good. JAMA Ophthalmology, 2017, 135, 268.	1.4	39
13	Vascular endothelial growth factor and diabetic macular edema. Survey of Ophthalmology, 2016, 61, 759-768.	1.7	54
14	Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid. Ophthalmology, 2016, 123, 1856-1864.	2.5	65
15	EFFECTIVENESS OF DIFFERENT MONITORING MODALITIES IN THE DETECTION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2016, 36, 1542-1547.	1.0	23
16	Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion. Ophthalmology, 2016, 123, 330-336.	2.5	204
17	Randomized Trial to Evaluate Tandospirone in Geographic Atrophy Secondary to Age-Related Macular Degeneration: The GATE Study. American Journal of Ophthalmology, 2015, 160, 1226-1234.	1.7	53
18	Intravitreal Aflibercept for Diabetic MacularÂEdema. Ophthalmology, 2015, 122, 2044-2052.	2.5	451

JEFFREY S HEIER

#	Article	IF	CITATIONS
19	Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion. Ophthalmology, 2015, 122, 538-544.	2.5	281
20	Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age-related macular degeneration. The HOme Monitoring of the Eye (HOME) study design — HOME Study report number 1. Contemporary Clinical Trials, 2014, 37, 294-300.	0.8	56
21	Intravitreal Aflibercept Injection for Macular Edema Due to Central Retinal Vein Occlusion. Ophthalmology, 2014, 121, 1414-1420.e1.	2.5	237
22	Noninfectious Inflammation After Intravitreal Injection of Aflibercept: Clinical Characteristics and Visual Outcomes. American Journal of Ophthalmology, 2014, 158, 733-737.e1.	1.7	69
23	Intravitreal Aflibercept for Diabetic Macular Edema. Ophthalmology, 2014, 121, 2247-2254.	2.5	668
24	Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration. Ophthalmology, 2014, 121, 193-201.	2.5	693
25	Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS Study. American Journal of Ophthalmology, 2013, 155, 429-437.e7.	1.7	313
26	Ranibizumab for Macular Edema Due to Retinal Vein Occlusions. Ophthalmology, 2012, 119, 802-809.	2.5	417
27	Vascular Endothelial Growth Factor Trap-Eye for Macular Edema Secondary to Central Retinal Vein Occlusion. Ophthalmology, 2012, 119, 1024-1032.	2.5	225
28	Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmology, 2012, 119, 2537-2548.	2.5	1,947
29	Primary Endpoint Results of a Phase II Study of Vascular Endothelial Growth Factor Trap-Eye in Wet Age-related Macular Degeneration. Ophthalmology, 2011, 118, 1089-1097.	2.5	94
30	The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed Dosing. Ophthalmology, 2011, 118, 1098-1106.	2.5	143
31	Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein Occlusion. Ophthalmology, 2011, 118, 2453-2460.	2.5	623
32	Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion. Ophthalmology, 2010, 117, 1102-1112.e1.	2.5	772
33	Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion. Ophthalmology, 2010, 117, 1134-1146.e3.	2.5	938
34	Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study. Ophthalmology, 2009, 116, 57-65.e5.	2.5	1,179
35	Ranibizumab for Neovascular Age-Related Macular Degeneration. New England Journal of Medicine, 2006, 355, 1419-1431.	13.9	5,190
36	Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration. New England Journal of Medicine, 2006, 355, 1432-1444.	13.9	3,221

#	Article	IF	CITATIONS
37	A Pilot Study of Multiple Intravitreal Injections of Ranibizumab in Patients with Center-Involving Clinically Significant Diabetic Macular Edema. Ophthalmology, 2006, 113, 1706-1712.	2.5	283